Search Results
Jun 08, 2026, 02:56 ET Share buybacks in Ericsson during the period June 1 - June 5, 2026
https://news.cision.com/ericsson/r/share-buybacks-in-ericsson-during-the-period-june-1---june-5--2026,c4358735The following files are available for download:
More news about: Ericsson
Jun 08, 2026, 02:47 ET Aker BP increases ownership interest in Johan Sverdrup following redetermination
https://news.cision.com/aker-bp-asa/r/aker-bp-increases-ownership-interest-in-johan-sverdrup-following-redetermination,c4358738
More news about: Aker BP ASA
Jun 08, 2026, 01:57 ET Sinch appoints Jonas Dahlberg as acting CEO to lead next phase of execution and growth
https://news.cision.com/sinch-ab/r/sinch-appoints-jonas-dahlberg-as-acting-ceo-to-lead-next-phase-of-execution-and-growth,c4358761The following files are available for download:
More news about: Sinch AB
Jun 08, 2026, 01:51 ET Clear Robotics Lands $1.75M to Build the World's Largest Fleet of Zero-Emission Autonomous Ships
Robotics' strategic expansion into Southeast Asia, India, and the Middle East. Funds will drive the development of larger unmanned vessels, advance R&D for automated port surveying, and scale proprietary commercial retrofit technology, preparing for open-ocean operations.Clear Robotics has a
More news about: Clear Robotics
Jun 08, 2026, 01:51 ET Sinch appoints Jonas Dahlberg as acting CEO to lead next phase of execution and growth
https://news.cision.com/sinch-ab/r/sinch-appoints-jonas-dahlberg-as-acting-ceo-to-lead-next-phase-of-execution-and-growth,c4358761The following files are available for download:
More news about: Sinch AB
Jun 07, 2026, 23:16 ET Sensing Meets Connectivity: Calterah Launches Ultra-Powerful mmWave Radar Chips for High-Performance ADAS and Leading-Edge UWB Radar Solutions
than 4T4R solutions.Andes-Pro features the world's first 6T6R ADAS radar SoC, achieving a 200 m detection range for weak targets and outstanding angular resolution (1° in azimuth; 3° in elevation). As a cost-effective alternative to expensive 8T8R products,
More news about: Calterah
Jun 07, 2026, 21:00 ET Uhale Adopts Quokka's Q-mast to Strengthen Application Security Testing
vulnerabilities, privacy risks, and compliance gaps earlier in the development process."Security is a continuous process," said Lewis Zhang, R&D General Manager at Uhale. "Adding Q-mast to our workflow is a practical step to strengthen our testing capabilities. It gives us additional visibility
More news about: Uhale
Jun 07, 2026, 20:10 ET 歌禮ASC30臨床數據與ASC37、ASC39令人振奮的臨床前結果於美國糖尿病協會（ADA）2026年度科學會議齊亮相，夯實差異化肥胖管線
3. 口服GLP-1R/GIPR/GCGR三靶點激動劑多肽：ASC37ASC37是一款利用歌禮專有的口服多肽遞送增強技術（POTENT）開發而成的口服GLP-1R/GIPR/GCGR三靶點激動劑多肽。通過抑制酶降解並增加胃腸道通透性，POTENT能夠將多肽的口服生物利用度從<1%提高至約3%–5%。在非人靈長類動物中，採用歌禮POTENT制劑的司美格魯肽的絕對口服生物利用度是採用其商業化SNAC（N-8-(2-羥基苯甲酰胺基)辛酸鈉）制劑的司美格魯肽的3倍；而採用歌禮POTENT制劑的替爾泊肽的絕對口服生物利用度是採用SNAC制劑的替爾泊肽的9倍。
More news about: 歌禮製藥有限公司
Jun 07, 2026, 20:10 ET Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
maintenance doses of 20 mg, 40 mg, and 60 mg, with dose titration periods of up to 20 weeks.3. Oral GLP-1R/GIPR/GCGR Triple Agonist Peptide: ASC37ASC37 is an oral GLP-1R/GIPR/GCGR triple agonist peptide developed using Ascletis' proprietary Peptide Oral Transport ENhancement Technology
More news about: Ascletis Pharma Inc.
Jun 07, 2026, 20:00 ET Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
and inflammatory diseases.About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs.
More news about: Antengene Corporation Limited
Jun 07, 2026, 17:30 ET Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
[email protected] ____________________ReferencesAroda Vanita R, Buzzetti R, Dalskov M, et al. Efficacy and safety of once-weekly CagriSema in adults with type 2 diabetes inadequately controlled on diet and exercise: a randomised,
More news about: NOVO NORDISK INC.
Jun 07, 2026, 17:30 ET Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications
Lancet."Treating type 2 diabetes early with a combined approach offers a unique opportunity to change the course of the disease," said Vanita R. Aroda, MD, lead author of the study. "Rather than focusing on glucose control alone, this strategy addresses weight, cardiovascular risk, and metabolic
More news about: American Diabetes Association
Jun 07, 2026, 16:45 ET AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
10.4330/wjc.v18.i2.114960. PMID: 41694036; PMCID: PMC12897005.Data on File; Amgen, 2025.Data on File; Amgen, 2025.Ndumele, C. E., & Blumenthal, R. S. (2025). VESALIUS and the Anatomy of High-Risk Prevention. New England Journal of Medicine.
More news about: Amgen
Jun 07, 2026, 08:00 ET Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026
States, Novo Nordisk has a 40-year presence, is headquartered in New Jersey and employs approximately 10,000 people across more than 10 manufacturing, R&D, and corporate locations in seven states plus Washington, D.C. For more information, visit
More news about: NOVO NORDISK INC.
Jun 06, 2026, 13:00 ET Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions
States, Novo Nordisk has a 40-year presence, is headquartered in New Jersey, and employs approximately 10,000 people across more than 10 manufacturing, R&D, and corporate locations in seven states plus Washington, D.C. For more information, visit
More news about: NOVO NORDISK INC.
Jun 06, 2026, 11:57 ET /C O R R E C T I O N -- U.S. Postal Service/
More news about: U.S. Postal Service
Jun 06, 2026, 09:07 ET People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
States, Novo Nordisk has a 40-year presence, is headquartered in New Jersey and employs approximately 10,000 people across more than 10 manufacturing, R&D, and corporate locations in seven states plus Washington, D.C. For more information, visit
More news about: Novo Nordisk
Jun 06, 2026, 09:01 ET People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
States, Novo Nordisk has a 40-year presence, is headquartered in New Jersey and employs approximately 10,000 people across more than 10 manufacturing, R&D, and corporate locations in seven states plus Washington, D.C. For more information, visit
More news about: Novo Nordisk
Jun 05, 2026, 20:30 ET 46 Greenberg Traurig Attorneys Recognized in 2026 IAM Patent 1000
Gary R. Jarosik: Prosecution (Illinois)Keith R. Jarosik:
More news about: Greenberg Traurig, LLP
Jun 05, 2026, 19:33 ET Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate
underscores its differentiation and the potential of next-generation molecules for obesity and metabolic diseases," said Patrice Lee, Ph.D., President, R&D."Importantly, AMB-702 has the potential for lower effective human dosing, which we believe could substantially improve scalability. We look
More news about: Ambrosia Biosciences
Jun 05, 2026, 19:30 ET Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026
States, Novo Nordisk has a 40-year presence, is headquartered in New Jersey, and employs approximately 10,000 people across more than 10 manufacturing, R&D, and corporate locations in seven states plus Washington, D.C. For more information, visit
More news about: NOVO NORDISK INC.
Jun 05, 2026, 18:54 ET Guild Wars 3, nowoczesne rozwinięcie formuły MMORPG, zapowiedziane na PC i PlayStation 5 podczas Summer Game Fest
legendarnej serii trafi na konsole.BELLEVUE, Waszyngton, 6 czerwca 2026 r. /PRNewswire/ -- renomowane studio deweloperskie ArenaNet® ogłosiło dziś wieczorem Guild Wars 3™, trzecią odsłonę legendarnej i uwielbianej serii MMORPG
More news about: NCSOFT
Jun 05, 2026, 18:00 ET FlackTek Adds Industry Veteran Dustin Becker to Expand Reach Across Advanced Manufacturing Markets and Accelerate Innovation-Driven Growth
process. To that end, FlackTek offers The FlackTek - a high-speed planetary mixer, supplies, and accessories for all scales of needs ranging from R&D to production, in-depth training, and world-class technical support and service.Design and manufacturing work for the FlackTek is done in the
More news about: FlackTek™
Jun 05, 2026, 17:01 ET Food Safety Testing Market Expected to Reach $44.1 Billion by 2033, at a CAGR of 7% : Allied Market Research
This further fuels the growth of the market, as millennials have a growing demand for processed foods. North America is further reinforced by strong R&D investments and sophisticated lab infrastructure, as well as novel technologies like PCR- and immunoassay-based Detection.Asia-Pacific:
More news about: Allied Market Research